Cargando…

Therapeutic Drug Monitoring of Busulfan in Patients Undergoing Hematopoietic Cell Transplantation: A Pilot Single-Center Study in Taiwan

Busulfan has been used as a conditioning regimen in allogeneic hematopoietic cell stem transplantation (HSCT). Owing to a large inter-individual variation in pharmacokinetics, therapeutic drug monitoring (TDM)-guided busulfan dosing is necessary to reduce graft failure and relapse rate. As there exi...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Rong-Long, Fang, Li-Hua, Yang, Xin-Yi, El Amrani, Mohsin, Uijtendaal, Esther Veronique, Chen, Yen-Fu, Ku, Wei-Chi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308703/
https://www.ncbi.nlm.nih.gov/pubmed/34206798
http://dx.doi.org/10.3390/ph14070613
_version_ 1783728344486903808
author Chen, Rong-Long
Fang, Li-Hua
Yang, Xin-Yi
El Amrani, Mohsin
Uijtendaal, Esther Veronique
Chen, Yen-Fu
Ku, Wei-Chi
author_facet Chen, Rong-Long
Fang, Li-Hua
Yang, Xin-Yi
El Amrani, Mohsin
Uijtendaal, Esther Veronique
Chen, Yen-Fu
Ku, Wei-Chi
author_sort Chen, Rong-Long
collection PubMed
description Busulfan has been used as a conditioning regimen in allogeneic hematopoietic cell stem transplantation (HSCT). Owing to a large inter-individual variation in pharmacokinetics, therapeutic drug monitoring (TDM)-guided busulfan dosing is necessary to reduce graft failure and relapse rate. As there exists no TDM of busulfan administration for HCT in Taiwan, we conducted a pilot study to assess the TDM-dosing of busulfan in the Taiwanese population; Seven patients with HCT from The Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan, received conditioning regimens consisting of intravenous busulfan and other chemotherapies. After the initial busulfan dose, blood samples were collected for busulfan TDM at 5 min, 1 h, 2 h, and 3 h. Busulfan was extracted and detected by performing stable-isotope dilution LC–MS/MS. Plasma busulfan concentration was quantified and used for dose adjustment. Potential adverse effects of busulfan, such as mucositis and hepatic veno-occlusive disease (VOD), were also evaluated; The LC–MS/MS method was validated with an analyte recovery of 88–99%, within-run and between-run precision of <15%, and linearity ranging from 10 to 10,000 ng/mL. Using TDM-guided busulfan dosing, dose adjustment was necessary and performed in six out of seven patients (86%) with successful engraftments in all patients (100%). Mild mucositis was observed, and VOD was diagnosed in only one patient; This single-center study in Taiwan demonstrated the importance of busulfan TDM in increasing the success rate of HCT transplantation. It is also necessary to further investigate the optimal busulfan target value in the Taiwanese population in the future.
format Online
Article
Text
id pubmed-8308703
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83087032021-07-25 Therapeutic Drug Monitoring of Busulfan in Patients Undergoing Hematopoietic Cell Transplantation: A Pilot Single-Center Study in Taiwan Chen, Rong-Long Fang, Li-Hua Yang, Xin-Yi El Amrani, Mohsin Uijtendaal, Esther Veronique Chen, Yen-Fu Ku, Wei-Chi Pharmaceuticals (Basel) Article Busulfan has been used as a conditioning regimen in allogeneic hematopoietic cell stem transplantation (HSCT). Owing to a large inter-individual variation in pharmacokinetics, therapeutic drug monitoring (TDM)-guided busulfan dosing is necessary to reduce graft failure and relapse rate. As there exists no TDM of busulfan administration for HCT in Taiwan, we conducted a pilot study to assess the TDM-dosing of busulfan in the Taiwanese population; Seven patients with HCT from The Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan, received conditioning regimens consisting of intravenous busulfan and other chemotherapies. After the initial busulfan dose, blood samples were collected for busulfan TDM at 5 min, 1 h, 2 h, and 3 h. Busulfan was extracted and detected by performing stable-isotope dilution LC–MS/MS. Plasma busulfan concentration was quantified and used for dose adjustment. Potential adverse effects of busulfan, such as mucositis and hepatic veno-occlusive disease (VOD), were also evaluated; The LC–MS/MS method was validated with an analyte recovery of 88–99%, within-run and between-run precision of <15%, and linearity ranging from 10 to 10,000 ng/mL. Using TDM-guided busulfan dosing, dose adjustment was necessary and performed in six out of seven patients (86%) with successful engraftments in all patients (100%). Mild mucositis was observed, and VOD was diagnosed in only one patient; This single-center study in Taiwan demonstrated the importance of busulfan TDM in increasing the success rate of HCT transplantation. It is also necessary to further investigate the optimal busulfan target value in the Taiwanese population in the future. MDPI 2021-06-26 /pmc/articles/PMC8308703/ /pubmed/34206798 http://dx.doi.org/10.3390/ph14070613 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chen, Rong-Long
Fang, Li-Hua
Yang, Xin-Yi
El Amrani, Mohsin
Uijtendaal, Esther Veronique
Chen, Yen-Fu
Ku, Wei-Chi
Therapeutic Drug Monitoring of Busulfan in Patients Undergoing Hematopoietic Cell Transplantation: A Pilot Single-Center Study in Taiwan
title Therapeutic Drug Monitoring of Busulfan in Patients Undergoing Hematopoietic Cell Transplantation: A Pilot Single-Center Study in Taiwan
title_full Therapeutic Drug Monitoring of Busulfan in Patients Undergoing Hematopoietic Cell Transplantation: A Pilot Single-Center Study in Taiwan
title_fullStr Therapeutic Drug Monitoring of Busulfan in Patients Undergoing Hematopoietic Cell Transplantation: A Pilot Single-Center Study in Taiwan
title_full_unstemmed Therapeutic Drug Monitoring of Busulfan in Patients Undergoing Hematopoietic Cell Transplantation: A Pilot Single-Center Study in Taiwan
title_short Therapeutic Drug Monitoring of Busulfan in Patients Undergoing Hematopoietic Cell Transplantation: A Pilot Single-Center Study in Taiwan
title_sort therapeutic drug monitoring of busulfan in patients undergoing hematopoietic cell transplantation: a pilot single-center study in taiwan
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308703/
https://www.ncbi.nlm.nih.gov/pubmed/34206798
http://dx.doi.org/10.3390/ph14070613
work_keys_str_mv AT chenronglong therapeuticdrugmonitoringofbusulfaninpatientsundergoinghematopoieticcelltransplantationapilotsinglecenterstudyintaiwan
AT fanglihua therapeuticdrugmonitoringofbusulfaninpatientsundergoinghematopoieticcelltransplantationapilotsinglecenterstudyintaiwan
AT yangxinyi therapeuticdrugmonitoringofbusulfaninpatientsundergoinghematopoieticcelltransplantationapilotsinglecenterstudyintaiwan
AT elamranimohsin therapeuticdrugmonitoringofbusulfaninpatientsundergoinghematopoieticcelltransplantationapilotsinglecenterstudyintaiwan
AT uijtendaalestherveronique therapeuticdrugmonitoringofbusulfaninpatientsundergoinghematopoieticcelltransplantationapilotsinglecenterstudyintaiwan
AT chenyenfu therapeuticdrugmonitoringofbusulfaninpatientsundergoinghematopoieticcelltransplantationapilotsinglecenterstudyintaiwan
AT kuweichi therapeuticdrugmonitoringofbusulfaninpatientsundergoinghematopoieticcelltransplantationapilotsinglecenterstudyintaiwan